Prizidilol, a combined vasodilatory and beta-adrenoceptor blocking drug, in primary hypertension. A long-term efficacy, tolerance and pharmacokinetic study.

Abstract

After an initial placebo period of four weeks 24 patients with primary hypertension were treated with prizidilol, a hydrazinopyridazine derivative with combined vasodilator and non-selective beta-adrenoceptor blocking actions, for a dose titration period of 14 weeks. Prizidilol 200 to 800 mg was given once daily to achieve a target supine diastolic blood pressure (BP) less than 90 mmHg. Supine and standing BP recorded 24-27 h after drug intake decreased from 172 +/- 17/106 +/- 6 mmHg (mean +/- SD) and 167 +/- 18/111 +/- 8 mmHg, respectively, after placebo to 159 +/- 16/99 +/- 8 and 154 +/- 18/101 +/- 9 mmHg after active treatment for six weeks (mean dose 447 mg), and to 154 +/- 16/97 +/- 7 and 148 +/- 14/97 +/- 7 mmHg after treatment for 14 weeks (mean dose 687 mg/day). A slight reduction in HR was seen after treatment for six weeks and in plasma renin activity and urinary methoxycatecholamine excretion after treatment for 14 weeks. A sustained decrease in BP was observed for 10 h after prizidilol 800 mg (n = 9), with a maximum antihypertensive effect (mean reduction in supine BP 33/18 mmHg) 2.5 h after dosing, which coincided with the mean peak plasma concentration. The plasma elimination half-life of the drug was 3.9 h (range 2.0-8.9 h). Changing to a twice daily regimen in 17 patients (mean daily dose 748 mg at six months) did not produce any further reduction in the BP (recorded 12-15 h after dosing) as compared to the once daily regimen at 14 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)

• Authors: B E Karlberg, R Larsson, K P Ohman, B Norlander, A Wirsen, J Hed, B L Lundh, A Flock
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 25 Issue 2 Pg. 179-86 ( 1983) ISSN: 0031-6970 [Print] Germany
• PMID: 6138257 (Publication Type: Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Antibodies, Antinuclear
• Pyridazines
• Vasodilator Agents
• prizidilol

Topics

• Acetylation
• Adrenergic beta-Antagonists (adverse effects, metabolism, therapeutic use)
• Adult
• Aged
• Antibodies, Antinuclear (analysis)
• Blood Pressure (drug effects)
• Electrocardiography
• Female
• Heart Rate (drug effects)
• Humans
• Hypertension (drug therapy)
• Kinetics
• Male
• Middle Aged
• Phenotype
• Pyridazines (adverse effects, metabolism, therapeutic use)
• Vasodilator Agents (adverse effects, metabolism, therapeutic use)